Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 1.00 |
| ▸ | RARA | P10276 | 9/20 | 1.00 |
| ▸ | RARG | P13631 | 9/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | BLVRB | P30043 | 1/20 | 0.84 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.74 |
| ▸ | RXRA | P19793 | 9/20 | 0.67 |
| ▸ | RXRB | P28702 | 8/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355626 | 1.00 | RARB (1.00) | RARBRARARARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL36207 | 0.91 | RARB (1.00) | RARBRARARARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL29373818 | 0.91 | RARB (1.00) | RARBRARARARGCYP26A1CYP3A4 | |
| Tamibarotene SCHEMBL21055743 | 0.90 | RARB (0.97) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL7621355 | 0.90 | RARA (0.82) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL8459704 | 0.89 | RARA (0.80) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL9446527 | 0.89 | CYP26A1 (0.80) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL1616078 | 0.87 | CYP26A1 (0.78) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL9446600 | 0.87 | RARA (0.78) | RARBRARARARGCYP26A1CYP3A4 | |
| SCHEMBL1616121 | 0.87 | CYP26A1 (0.78) | RARBRARARARGCYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1095 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12605434-B2 | Composition for preventing or treating autoimmune diseases | STATENS SERUM INSTITUT (DK) | 2026-04-21 | — | — | US | claimed |
| EP-4713433-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | Children's Hospital Medical Center (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2026-02-26 | — | — | US | claimed |
| EP-4689067-A2 | CLINICAL-GRADE ORGANOIDS | Children's Hospital Medical Center (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | CHILDRENS HOSPITAL MED CT (US) | 2026-01-01 | — | — | US | claimed |
| US-20250382580-A1 | COMPOSITIONS AND METHODS FOR ACCELERATED PRODUCTION OF THYMIC CELLS FROM PLURIPOTENT STEM CELLS | UNIV COLORADO REGENTS (US) | 2025-12-18 | — | — | US | claimed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250345316-A1 | METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | claimed |
| US-5854292-A | Stimulating the differentiation of preadipocytic cells and therapies based thereon | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-12-29 | — | — | US | claimed |
| US-5827897-A | INSULIN-RESISTANCE IN A MAMMAL TREATED BY ADMINISTERING A SYNERGISTIC MIXTURE OF A RETINOID AND A FATTY ACID; ANTIDIABETIC AGENTS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-10-27 | — | — | US | claimed |
| US-5827500-A | TOPICAL SKIN TESTING THE ANIMAL RESPONSES BY APPLYING RETINOIC ACID RECEPTOR AGONIST AND ANTAGONIST | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-10-27 | — | — | US | claimed |
| US-5767148-A | 4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHYL) CARBONYLBENZOIC ACID ETHYLENE ACETAL AND 4-((5,6,7,8-TETRAHYDRO-5,5,8,8-TETRAMETHYL-2-NAPHTHYL) CARBOXYLAMIDOBENZOIC ACID HAVING RETINOID ACTIVITYP; LEUKEMIA | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-06-16 | — | — | US | claimed |
| US-5728739-A | LIGANDS WITH AFFINITY FOR RETINOIC ACID RECEPTORS IN SYNERGISTIC COMBINATION WITH A FATTY ACID, TREATMENT OF DIABETES, CARDIOVASCULAR DISEASE, ATHEROSCLEROSIS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-03-17 | — | — | US | claimed |
| US-5696104-A | TOPICALLY APPLYING TO SKIN OF MAMMAL ACTIVE LIGAND FOR MEMBER OF STEROIDAL/THYROIDAL RECEPTORS, ADMINISTERING TOPICALLY OR SYSTEMICALLY MOLECULE TO BE TESTED, EVALUATING SKIN RESPONSE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1997-12-09 | — | — | US | claimed |
| EP-0694301-B1 | Synergistic combination containing at least a RXR specific ligand and a RAR alpha specific ligand | CIRD GALDERMA (FR) | 1996-11-13 | — | — | EP | claimed |
| US-5556844-A | SYNERGISTIC, SKIN DISORDERS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-09-17 | — | — | US | claimed |
| EP-0465343-B1 | Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association | CIRD GALDERMA (FR) | 1994-06-15 | — | — | EP | claimed |
| WO-1993015740-A1 | METHODS OF TREATING INFLAMMATORY DERMATOSES | KLIGMAN ALBERT M (US) | 1993-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | PKD1, RARB, PKD2 | RARB 2/4885RARA 4/4885RARG 9/4885 |
| US-12605434-B2 | Composition for preventing or treating autoimmune diseases | TMSB10, RXRB, MALT1 | RARB 8/4885RARA 9/4885RARG 7/4885 |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | BMP4, RARB, WNT3A | RARB 2/4885RARA 4/4885RARG 5/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | RARB 70/4885RARA 354/4885RARG 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.